(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 June 2023 (22.06.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/111802 A1

(51) International Patent Classification:
A61P 37/08 (2006.01) *A61K 31/505* (2006.01)

(21) International Application Number:
PCT/IB2022/062046

(22) International Filing Date:
12 December 2022 (12.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/289,273	14 December 2021 (14.12.2021)	US
63/290,916	17 December 2021 (17.12.2021)	US
63/304,086	28 January 2022 (28.01.2022)	US
63/369,017	21 July 2022 (21.07.2022)	US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: **BHATTACHARYA, Souvik**; 420 Thicket St, Weymouth, Massachusetts 02190 (US). **BIETH, Bruno**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **CENNI, Bruno**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **GRAHAM, Gordon**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **JUHNKE, Michael**; F. Hoffmann-La Roche AG, Building 10/Room O02, 4070 Basel (CH). **LIGUEROS-SAYLAN, Monica**; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936 (US). **MIHAILESCU, Dan Dragos**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **STUART, Bridget Danielle**; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936 (US). **SIN, Kim-Hien**; Novartis Pharma AG, Postfach, 4002 Basel (CH). **RAPP, Karin**; Novartis Pharma AG, Postfach, 4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2023/111802 A1

(54) Title: METHODS OF TREATMENT USING LOU064

(57) Abstract: The present disclosure relates to methods of treating and/or preventing IgE driven allergic reaction to one or more allergens, preferably food allergens, in subjects having such disease or condition, comprising administering a therapeuticallly effective dose of LOU064.